Senseonics Finds Insulin Pump Partner for its 365-Day Glucose Monitor

Sequel Med Tech, a company developing insulin delivery technologies, and Senseonics, a medical technology company focused on the development and manufacturing of long-term, implantable CGM systems for people with diabetes, announced their commercial development agreement to integrate Sequel’s twiist Automated Insulin Delivery (AID) System powered by Tidepool with Senseonics’ Eversense 365 CGM.

Through this collaboration, the twiist Automated Insulin Delivery (AID) System will become the first AID system compatible with the Senseonics Eversense 365, a one-year CGM system.

Sequel said that people living with type 1 diabetes who choose to use twiist will be able to select from two compatible CGM partners, the Senseonics Eversense 365 and Abbott’s FreeStyle Libre 3 Plus sensor.

twiist features flexible wear options and a 300-unit insulin capacity. Users can manage their insulin directly from their iPhone and optional connected Apple Watch.